Category

Press Release

T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease

$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional new investments from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Samsara BioCapital, M-Ventures and Lilly, joined by all existing major shareholders Proceeds to fund…
Read More

T-Therapeutics appoints Theodora Harold as Chief Executive Officer, reflecting Company’s ambitious growth plans and progression into therapeutic development

Theodora has over 25 years’ experience in the biotech sector, with a proven track record of dynamic leadership. 10 March 2025; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble T cell receptor (TCR) therapeutics targeting cancer and autoimmune indications, announces the…
Read More